
https://www.science.org/content/blog-post/microbiome-connections-disease-get-stronger
# Microbiome Connections to Disease Get Stronger (September 2017)

## 1. SUMMARY

This 2017 commentary reviews emerging evidence linking gut microbiome composition to multiple sclerosis (MS), while acknowledging the field's challenges with reproducibility and causality. The article highlights three key studies: two papers in PNAS showing that MS patients exhibit elevated *Akkermansia* (and in one study *Acinetobacter*) with reduced *Parabacteroides*, and demonstrating through fecal transplants into mouse EAE models that these microbial shifts can directly exacerbate disease pathology. A complementary Nature paper identified that gut bacteria produce N-acyl amides that act as ligands for human GPCRs, providing a potential mechanism for microbiome-host signaling relevant to inflammation and metabolism. The author emphasizes that while the field shows genuine promise with improving evidence for causality, therapeutic applications remain premature given uncertainty about specific bacterial culprits and mechanisms.

## 2. HISTORY

**Scientific validation and mechanisms (2017-2024):**
- Subsequent research has largely validated the MS-microbiome connection, with systematic reviews confirming dysbiosis patterns (including *Akkermansia* increases) in MS patients
- The mechanistic link strengthened: studies demonstrated that gut microbiome metabolites can directly modulate immune cell function, including T-cell differentiation and regulatory T-cell populations implicated in MS
- *Akkermansia muciniphila* specifically emerged as a "keystone" species associated with inflammatory conditions, though with complex context-dependent effects

**Therapeutic development:**
- **Fecal Microbiota Transplantation (FMT)** has advanced significantly, with FDA approval for recurrent *C. difficile* infections (2013), but remains investigational for autoimmune conditions including MS
- Several clinical trials of microbiome modulation for MS have been conducted, including FMT and probiotic interventions, with modest or mixed results
- No FDA-approved microbiome-based therapy for MS currently exists
- Companies like Seres Therapeutics, Vedanta Biosciences, and Finch Therapeutics advanced microbiome drug development platforms, though most focused on *C. difficile* and inflammatory bowel disease rather than MS

**Methodological evolution:**
- Standardization of microbiome analysis improved with multi-omics approaches (metagenomics, metabolomics) and better reference databases
- Stool sampling limitations noted in the article remain partially unresolved, though mucosal sampling and spatial mapping techniques have advanced
- Causality assessment improved through gnotobiotic animal models and more sophisticated statistical methods

**Market and industry:**
- The microbiome therapeutics market grew substantially but faced setbacks, with notable clinical trial failures and regulatory challenges
- Investment peaked around 2018-2020, followed by consolidation and strategic pivots toward more tractable indications

## 3. PREDICTIONS

**Author's predictions and outcomes:**

• **Prediction:** "it's way too early to start talking about the therapeutic implications [...] we'd better be able to agree on just which bacteria are responsible and how they might be having their effects"  
**Reality:** ✅ **Accurate** - No microbiome-based MS therapy reached market approval by 2024, and scientific consensus on specific bacterial targets remains incomplete

• **Prediction:** "I would be very skeptical of anyone claiming (at this early stage) to have a great new therapeutic microbiome breakthrough for something as complex as MS"  
**Reality:** ✅ **Accurate** - Despite numerous clinical trials, no breakthrough therapy emerged; most interventions showed modest or inconclusive results

• **Implication (from text):** The signaling mechanisms (GPCR ligation by bacterial metabolites) would prove significant  
**Reality:** ✅ **Partially validated** - Microbiome metabolite-GPCR interactions have been extensively documented as important immunomodulatory pathways, though therapeutic exploitation remains incomplete

• **General confidence in the field:** "the field in general is real stuff, generating some very interesting real results"  
**Reality:** ✅ **Accurate** - The microbiome-disease connection became firmly established in mainstream medical research, with thousands of publications and ongoing clinical development

**Broader context on drug development:**
- The author's caution about therapeutic timelines proved prescient; developing microbial therapeutics faces unique regulatory and manufacturing challenges
- MS drug development shifted toward more targeted immunomodulation (B-cell depletion, S1P modulators) rather than microbiome manipulation, though diet and gut health remain adjunctive considerations
- The complexity noted (chicken-or-egg problem, taxonomic disagreements, sampling issues) continued to challenge translation into predictive biomarkers

## 4. INTEREST

Rating: **7/10**

This article demonstrates excellent scientific journalism by accurately calibrating enthusiasm with appropriate skepticism. It correctly identified both the genuine scientific potential and the substantial translational barriers, making predictions that held up remarkably well over seven years. The focus on mechanistic evidence and causality assessment reflects deeper understanding than typical science journalism of the period.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170913-microbiome-connections-disease-get-stronger.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_